114 results
Page 2 of 6
8-K
EX-99.2
ch0eeteuxpc9pm
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-99.1
6kikn0xc qf1a
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
544md
18 Dec 23
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
4:12pm
8-K
EX-3.1
icoz2q7
12 Dec 23
Amendments to Articles of Incorporation or Bylaws
4:35pm
8-K
EX-99.1
61eazml18
7 Nov 23
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
8-K
EX-1.1
6nok3ui
13 Sep 23
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
5:23pm
424B5
3l23up72sd irc34y36
13 Sep 23
Prospectus supplement for primary offering
5:19pm
424B5
14b gcr2v
11 Sep 23
Prospectus supplement for primary offering
4:09pm
8-K
wvumhvw62 ixr41
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
8h8vwe7cgjvgijqr7oqf
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.2
lqkbfa0gyxlmtt8gsdd3
11 Sep 23
Regulation FD Disclosure
6:05am
8-K
EX-99.1
clnpj
8 Aug 23
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:01am
8-K
EX-99.1
tzgbzpu4i hf6m
14 Nov 22
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:15am
8-K
ckigj8dc7bn1i9sua8
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am